NUTX Stock Forecast & Price Target

Nutex Health is supported by a compelling combination of improving reimbursement visibility, disciplined capital allocation, and rapid de novo expansion, making the underlying earnings stream look more durable than the market has historically assumed. The Fifth Circuit’s TMA III ruling, lower IDR fees, and management’s >85% win rate and >80% collections on awards should improve first-pass payments, reduce claims volatility, and lift revenue per visit from the ~$4,000–$4,200 normalized range. At the same time, 2025 operating cash flow of $248M, $109.7M in 1H26, cash of $205.2M, and plans for 10+ openings through 2028 with about $10M EBITDA per mature unit show a self-funding growth engine with attractive peer-discounted valuation.

Nutex Health is exposed to significant fundamental pressure from physician and nursing shortages, which can constrain patient volumes and prevent the company from meeting revenue and earnings forecasts. Its dependence on out-of-network reimbursement through the federal IDR process makes profitability highly vulnerable to CMS rule changes, reimbursement cuts, and litigation risk, while competitive pressure from retail clinics, telemedicine, and other alternatives can divert demand away from its facilities. Results are also difficult to forecast because profitability is concentrated in arbitration-derived reimbursements, and execution, financing, and governance risks tied to sale-leasebacks, related-party leases, and concentrated leadership could further weaken balance sheet strength.